A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer

Farasat Kazmi(University of Oxford), Sarah P. Blagden(Churchill Hospital), Hani Gabra(Royal Children's Hospital), Essam Ghazaly(Queen Mary University of London), Laura Spiers(Churchill Hospital), René L. Roux(Churchill Hospital), David J. Harrison(NHS Lothian), Shibani Nicum(London Cancer), Chat Gnanaranjan(London Cancer), Nigel McCracken(Scotland's Rural College), Ajithkumar Sukumaran(Imperial College London)
Clinical Cancer Research
March 19, 2021
10.1158/1078-0432.ccr-20-4403
Cited by 10

Related Papers

Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
|Annals of Oncology|2024|277
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
|The Lancet|2019|223